Brandenburg Kapital - News about Pentracor GmbH

Pentracor presents positive trial results for CRP apheresis therapy in myocardial infarction patients

Henningsdorf/Berlin - März 2021. With the publication of the clinical study on myocardial infarction patients “C-Reactive Protein Apheresis as Anti-inflammatory Therapy in Acute Myocardial Infarction: Results of the CAMI-1 Study” in the renowned journal “Frontiers in Cardiovascular Medicine”, Pentracor, a portfolio company of Brandenburg Kapital, was able to achieve a further milestone in establishing its CRP apheresis therapy in the medical technology market.

The study clearly demonstrated that CRP concentration is directly related to infarct size. It could also be shown that the use of CRP apheresis therapy significantly reduces the infarct size of myocardial infarctions and significantly improves cardiac function and performance compared to the control group.

Pentracor produces and markets a specific adsorber for the therapeutic lowering of C-reactive protein (CRP) from the blood plasma of heart attack patients to reduce damage to the heart. With CRP apheresis and the PentraSorb® filter product, it is pursuing a new approach in the acute treatment of heart attacks to minimize subsequent damage. Today, several hospitals in Germany are already successfully using CRP apheresis.

Please read more information about Pentracor GmbH below in the download section.

For more information, see and